Diagnostic accuracy and clinical utility of micro-ultrasound guided biopsies in patients with suspected prostate cancer.
diagnosis
prostate cancer
ultrasonography
Journal
Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
09
2022
revised:
29
11
2022
accepted:
18
12
2022
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
ppublish
Résumé
New technologies to improve quality of prostate biopsies are appearing in clinical practice.We evaluate the performance of a micro-ultrasound device and the Prostate Risk Identification using MicroUltraSound (PRI-MUS) score in detecting clinically significant prostate cancer (csPCa). We retrospectively reviewed data of 139 biopsy- naïve patients with suspicion of prostate cancer, who underwent diagnostic MRI and micro-ultrasonography (microUS), followed by transrectal prostatic biopsy (systematic ±targeted) under local anesthetic. The main objective was to evaluate the performance of the Prostate Risk Identification using MicroUltraSound (PRI-MUS) score in detecting csPCa, defined as International Society of Urological Pathology (ISUP) ≥2. Of all patients, 97 (70%) were found to have PCa, and 62 (45%) having csPCa.Among 100 patients with positive microUS (PRI-MUS score ≥3), 23 (23%) had ncsPCa and 57 (57%) were diagnosed with csPCa (ISUP ≥2); and in 39 patients with negative microUS, 12 (31%) were diagnosed with ncsPCa and 5 (13%) with csPCa.A PRI-MUS score ≥3 presented a sensitivity, specificity, positive predictive value and negative predictive value of 92%, 44%, 57% and 95%, respectively, for the detection of csPCa.The PRI-MUS score had higher areas under the curve than Prostate Imaging Reporting & Data System (PI-RADS) both for targeted (AUC 0.801 vs 0.733) and systematic + targeted (AUC 0.776 vs 0.694) biopsies for csPCa detection. In our cohort, microUS performed well as a diagnostic tool through an easily implementable scale. MicroUS presented similar sensitivity and higher specificity than MRI in detecting csPCa. Further multicenter prospective studies may clarify its role in prostate cancer diagnosis.
Identifiants
pubmed: 37064256
doi: 10.5173/ceju.2023.198
pii: 198
pmc: PMC10091889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-32Informations de copyright
Copyright by Polish Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Eur Urol Oncol. 2019 May;2(3):329-332
pubmed: 31200848
Acad Radiol. 2017 Sep;24(9):1101-1106
pubmed: 28546032
J Urol. 2020 May;203(5):918-925
pubmed: 31821099
J Urol. 2020 Oct;204(4):726-733
pubmed: 32314932
Urol Oncol. 2021 Dec;39(12):832.e1-832.e7
pubmed: 34183255
Eur Urol Focus. 2021 Nov;7(6):1292-1299
pubmed: 32654967
Can Urol Assoc J. 2021 Jan;15(1):E11-E16
pubmed: 32701437
Eur Urol Focus. 2021 Sep;7(5):1019-1026
pubmed: 33069624
World J Urol. 2020 May;38(5):1201-1206
pubmed: 31309290
Eur Radiol. 2020 Sep;30(9):4838-4846
pubmed: 32350662
BJU Int. 2018 Jul;122(1):50-58
pubmed: 29388388
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
BJU Int. 2022 May;129(5):648-654
pubmed: 34773679
Prostate Cancer Prostatic Dis. 2019 Dec;22(4):546-551
pubmed: 30842585
Am J Surg Pathol. 2020 Aug;44(8):e87-e99
pubmed: 32459716
J Urol. 2016 Aug;196(2):562-9
pubmed: 26791931
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663
pubmed: 31022301